Table 1.
List of different assays used.
Fig 1.
Flowchart demonstrating follow-up rates for each timepoint as well as availability of Anti-S, Anti-N and neutralising antibodies (NABs) during the timepoints.
Table 2.
Comparison of participant characteristics between young control and older persons.
Table 3.
Comparison of types of vaccines received, booster uptake, and median time intervals between time points.
Table 4.
Geometric mean concentrations of anti–S antibodies by vaccination stage, infection status, and vaccine platforms across all the four timepoints.
Table 5.
Neutralising antibodies (NABs) results against SARS-CoV-2 wild-type, Delta, and Omicron strains by vaccination stage, infection status, and vaccine platforms.
Table 6.
Univariable and multivariable predictors of anti-spike antibody levels at 6–9 months after first booster vaccination (TP3).
Table 7.
Univariable and multivariable predictors of anti-spike antibody levels at 3 months after second booster vaccination (TP4).
Fig 2.
Anti-S antibody levels acrossTP1-TP4 stratified by SARS-CoV-2 infection status.